Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 32 of 32 entries
Sorted by: Best Match Show Resources per page
The Comparison of the Risk-Sharing Schemes Proposed in Reimbursement Applications Received By Ahtapol In 2012 and 2013.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Zawodnik S, Iwanczuk T, Hermanowski TR, Matusewicz W.
PMID: 27201224
Value Health. 2014 Nov;17(7):A448-9. doi: 10.1016/j.jval.2014.08.1202. Epub 2014 Oct 26.

No abstract available.

Cite
Zawodnik S, Iwanczuk T, Hermanowski TR, et al. The Comparison of the Risk-Sharing Schemes Proposed in Reimbursement Applications Received By Ahtapol In 2012 and 2013. Value Health. 2014;17(7):A448-9doi: 10.1016/j.jval.2014.08.1202.
Zawodnik, S., Iwanczuk, T., Hermanowski, T. R., & Matusewicz, W. (2014). The Comparison of the Risk-Sharing Schemes Proposed in Reimbursement Applications Received By Ahtapol In 2012 and 2013. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A448-9. https://doi.org/10.1016/j.jval.2014.08.1202
Zawodnik, S, et al. "The Comparison of the Risk-Sharing Schemes Proposed in Reimbursement Applications Received By Ahtapol In 2012 and 2013." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A448-9. doi: https://doi.org/10.1016/j.jval.2014.08.1202
Zawodnik S, Iwanczuk T, Hermanowski TR, Matusewicz W. The Comparison of the Risk-Sharing Schemes Proposed in Reimbursement Applications Received By Ahtapol In 2012 and 2013. Value Health. 2014 Nov;17(7):A448-9. doi: 10.1016/j.jval.2014.08.1202. Epub 2014 Oct 26. PMID: 27201224.
Copy Download .nbib Format: NLM
Homozygous familial hypercholesterolemia (HoFH) in Germany: an epidemiological survey.

ClinicoEconomics and outcomes research : CEOR

Walzer S, Travers K, Rieder S, Erazo-Fischer E, Matusiewicz D.
PMID: 23662069
Clinicoecon Outcomes Res. 2013 May 03;5:189-92. doi: 10.2147/CEOR.S43087. Print 2013.

INTRODUCTION: In Europe a disease is recognized as rare if less than 1 in 2000 people suffer from the specific disease. In patients with familial homozygous hypercholesterolemia (HoFH) the accumulation of low-density lipoprotein cholesterol (LDL-C) leads to generalized atherosclerosis...

Cite
Walzer S, Travers K, Rieder S, et al. Homozygous familial hypercholesterolemia (HoFH) in Germany: an epidemiological survey. Clinicoecon Outcomes Res. 2013;5:189-92doi: 10.2147/CEOR.S43087.
Walzer, S., Travers, K., Rieder, S., Erazo-Fischer, E., & Matusiewicz, D. (2013). Homozygous familial hypercholesterolemia (HoFH) in Germany: an epidemiological survey. ClinicoEconomics and outcomes research : CEOR, 5189-92. https://doi.org/10.2147/CEOR.S43087
Walzer, S, et al. "Homozygous familial hypercholesterolemia (HoFH) in Germany: an epidemiological survey." ClinicoEconomics and outcomes research : CEOR vol. 5 (2013): 189-92. doi: https://doi.org/10.2147/CEOR.S43087
Walzer S, Travers K, Rieder S, Erazo-Fischer E, Matusiewicz D. Homozygous familial hypercholesterolemia (HoFH) in Germany: an epidemiological survey. Clinicoecon Outcomes Res. 2013 May 03;5:189-92. doi: 10.2147/CEOR.S43087. Print 2013. PMID: 23662069; PMCID: PMC3647446.
Copy Download .nbib Format: NLM
Immunoliposomes with Simvastatin as a Potential Therapeutic in Treatment of Breast Cancer Cells Overexpressing HER2-An In Vitro Study.

Cancers

Matusewicz L, Podkalicka J, Sikorski AF.
PMID: 30388834
Cancers (Basel). 2018 Nov 01;10(11). doi: 10.3390/cancers10110418.

Lipophilic statins are promising candidates for breast cancer treatment. However, anticancer therapy requires much higher doses of statins than can be delivered orally, and such high doses are known to exert more adverse effects. The main objective of our...

Cite
Matusewicz L, Podkalicka J, Sikorski AF. Immunoliposomes with Simvastatin as a Potential Therapeutic in Treatment of Breast Cancer Cells Overexpressing HER2-An In Vitro Study. Cancers (Basel). 2018;10(11)doi: 10.3390/cancers10110418.
Matusewicz, L., Podkalicka, J., & Sikorski, A. F. (2018). Immunoliposomes with Simvastatin as a Potential Therapeutic in Treatment of Breast Cancer Cells Overexpressing HER2-An In Vitro Study. Cancers, 10(11), . https://doi.org/10.3390/cancers10110418
Matusewicz, Lucyna, et al. "Immunoliposomes with Simvastatin as a Potential Therapeutic in Treatment of Breast Cancer Cells Overexpressing HER2-An In Vitro Study." Cancers vol. 10,11 (2018). doi: https://doi.org/10.3390/cancers10110418
Matusewicz L, Podkalicka J, Sikorski AF. Immunoliposomes with Simvastatin as a Potential Therapeutic in Treatment of Breast Cancer Cells Overexpressing HER2-An In Vitro Study. Cancers (Basel). 2018 Nov 01;10(11). doi: 10.3390/cancers10110418. PMID: 30388834; PMCID: PMC6266203.
Copy Download .nbib Format: NLM
Effect of .

PeerJ

Zglińska K, Niemiec T, Łozicki A, Matusiewicz M, Szczepaniak J, Puppel K, Kutwin M, Jaworski S, Rygało-Galewska A, Koczoń P.
PMID: 33552740
PeerJ. 2021 Jan 19;9:e10760. doi: 10.7717/peerj.10760. eCollection 2021.

METHODS: Because the main biologically active compounds of RESULT: The extract increased HFFF-2 cell proliferation and reduced cell death caused by HCONCLUSION: EUE protected human fibroblasts from H

Cite
Zglińska K, Niemiec T, Łozicki A, et al. Effect of . PeerJ. 2021;9:e10760doi: 10.7717/peerj.10760.
Zglińska, K., Niemiec, T., Łozicki, A., Matusiewicz, M., Szczepaniak, J., Puppel, K., Kutwin, M., Jaworski, S., Rygało-Galewska, A., & Koczoń, P. (2021). Effect of . PeerJ, 9e10760. https://doi.org/10.7717/peerj.10760
Zglińska, Klara, et al. "Effect of ." PeerJ vol. 9 (2021): e10760. doi: https://doi.org/10.7717/peerj.10760
Zglińska K, Niemiec T, Łozicki A, Matusiewicz M, Szczepaniak J, Puppel K, Kutwin M, Jaworski S, Rygało-Galewska A, Koczoń P. Effect of . PeerJ. 2021 Jan 19;9:e10760. doi: 10.7717/peerj.10760. eCollection 2021. PMID: 33552740; PMCID: PMC7821754.
Copy Download .nbib Format: NLM
Delay Discounting and Preference Reversals by Cigarette Smokers.

The Psychological record

Yi R, Matusiewicz AK, Tyson A.
PMID: 27141125
Psychol Rec. 2016 Jun 01;66(2):235-242. doi: 10.1007/s40732-016-0165-4. Epub 2016 Feb 03.

Quit attempts made by smokers that result in relapse to smoking are conceptualized in behavioral economics as preference reversals, in which preference for a larger-later outcome switches to preference for a smaller-sooner outcome. Though preference reversals are predicted by...

Cite
Yi R, Matusiewicz AK, Tyson A. Delay Discounting and Preference Reversals by Cigarette Smokers. Psychol Rec. 2016;66(2):235-242doi: 10.1007/s40732-016-0165-4.
Yi, R., Matusiewicz, A. K., & Tyson, A. (2016). Delay Discounting and Preference Reversals by Cigarette Smokers. The Psychological record, 66(2), 235-242. https://doi.org/10.1007/s40732-016-0165-4
Yi, Richard, et al. "Delay Discounting and Preference Reversals by Cigarette Smokers." The Psychological record vol. 66,2 (2016): 235-242. doi: https://doi.org/10.1007/s40732-016-0165-4
Yi R, Matusiewicz AK, Tyson A. Delay Discounting and Preference Reversals by Cigarette Smokers. Psychol Rec. 2016 Jun 01;66(2):235-242. doi: 10.1007/s40732-016-0165-4. Epub 2016 Feb 03. PMID: 27141125; PMCID: PMC4850733.
Copy Download .nbib Format: NLM
Prevalence of HCV genotypes in Poland - the EpiTer study.

Clinical and experimental hepatology

Flisiak R, Pogorzelska J, Berak H, Horban A, Orłowska I, Simon K, Tuchendler E, Madej G, Piekarska A, Jabłkowski M, Deroń Z, Mazur W, Kaczmarczyk M, Janczewska E, Pisula A, Smykał J, Nowak K, Matukiewicz M, Halota W, Wernik J, Sikorska K, Mozer-Lisewska I, Rozpłochowski B, Garlicki A, Tomasiewicz K, Krzowska-Firych J, Baka-Ćwierz B, Kryczka W, Zarębska-Michaluk D, Olszok I, Boroń-Kaczmarska A, Sobala-Szczygieł B, Szlauer B, Korcz-Ondrzejek B, Sieklucki J, Pleśniak R, Ruszała A, Postawa-Kłosińska B, Citko J, Lachowicz-Wawrzyniak A, Musialik J, Jezierska E, Dobracki W, Dobracka B, Hałubiec J, Krygier R, Strokowska A, Chomczyk W, Witczak-Malinowska K.
PMID: 28856279
Clin Exp Hepatol. 2016 Dec;2(4):144-148. doi: 10.5114/ceh.2016.63871. Epub 2016 Nov 28.

THE AIM OF THE STUDY: Was to assess current prevalence of hepatitis C virus (HCV) genotypes in Poland, including their geographic distribution and changes in a given period of time.MATERIAL AND METHODS: Data were collected with questionnaires from 29...

Cite
Flisiak R, Pogorzelska J, Berak H, et al. Prevalence of HCV genotypes in Poland - the EpiTer study. Clin Exp Hepatol. 2016;2(4):144-148doi: 10.5114/ceh.2016.63871.
Flisiak, R., Pogorzelska, J., Berak, H., Horban, A., Orłowska, I., Simon, K., Tuchendler, E., Madej, G., Piekarska, A., Jabłkowski, M., Deroń, Z., Mazur, W., Kaczmarczyk, M., Janczewska, E., Pisula, A., Smykał, J., Nowak, K., Matukiewicz, M., Halota, W., Wernik, J., Sikorska, K., Mozer-Lisewska, I., Rozpłochowski, B., Garlicki, A., Tomasiewicz, K., Krzowska-Firych, J., Baka-Ćwierz, B., Kryczka, W., Zarębska-Michaluk, D., Olszok, I., Boroń-Kaczmarska, A., Sobala-Szczygieł, B., Szlauer, B., Korcz-Ondrzejek, B., Sieklucki, J., Pleśniak, R., Ruszała, A., Postawa-Kłosińska, B., Citko, J., Lachowicz-Wawrzyniak, A., Musialik, J., Jezierska, E., Dobracki, W., Dobracka, B., Hałubiec, J., Krygier, R., Strokowska, A., Chomczyk, W., & Witczak-Malinowska, K. (2016). Prevalence of HCV genotypes in Poland - the EpiTer study. Clinical and experimental hepatology, 2(4), 144-148. https://doi.org/10.5114/ceh.2016.63871
Flisiak, Robert, et al. "Prevalence of HCV genotypes in Poland - the EpiTer study." Clinical and experimental hepatology vol. 2,4 (2016): 144-148. doi: https://doi.org/10.5114/ceh.2016.63871
Flisiak R, Pogorzelska J, Berak H, Horban A, Orłowska I, Simon K, Tuchendler E, Madej G, Piekarska A, Jabłkowski M, Deroń Z, Mazur W, Kaczmarczyk M, Janczewska E, Pisula A, Smykał J, Nowak K, Matukiewicz M, Halota W, Wernik J, Sikorska K, Mozer-Lisewska I, Rozpłochowski B, Garlicki A, Tomasiewicz K, Krzowska-Firych J, Baka-Ćwierz B, Kryczka W, Zarębska-Michaluk D, Olszok I, Boroń-Kaczmarska A, Sobala-Szczygieł B, Szlauer B, Korcz-Ondrzejek B, Sieklucki J, Pleśniak R, Ruszała A, Postawa-Kłosińska B, Citko J, Lachowicz-Wawrzyniak A, Musialik J, Jezierska E, Dobracki W, Dobracka B, Hałubiec J, Krygier R, Strokowska A, Chomczyk W, Witczak-Malinowska K. Prevalence of HCV genotypes in Poland - the EpiTer study. Clin Exp Hepatol. 2016 Dec;2(4):144-148. doi: 10.5114/ceh.2016.63871. Epub 2016 Nov 28. PMID: 28856279; PMCID: PMC5497426.
Copy Download .nbib Format: NLM
[Intercultural Opening in Health Care Promotes Solidarity].

Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany))

Beck P, Mratschkowski A, Matusiewicz D.
PMID: 33096580
Gesundheitswesen. 2020 Oct 23; doi: 10.1055/a-1236-3630. Epub 2020 Oct 23.

AIM: Due to the increase in socio-cultural diversity, the importance of intercultural opening processes is also increasing in the German health care system. The present study examines on the basis of 4 case studies to what extent an organisationally...

Cite
Beck P, Mratschkowski A, Matusiewicz D. Interkulturelle Öffnung im Gesundheitswesen fördert einen solidarischen Umgang. [Intercultural Opening in Health Care Promotes Solidarity]. Gesundheitswesen. 2020;doi: 10.1055/a-1236-3630.
Beck, P., Mratschkowski, A., & Matusiewicz, D. (2020). Interkulturelle Öffnung im Gesundheitswesen fördert einen solidarischen Umgang. [Intercultural Opening in Health Care Promotes Solidarity]. Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)), . https://doi.org/10.1055/a-1236-3630
Beck, Patricia, et al. "Interkulturelle Öffnung im Gesundheitswesen fördert einen solidarischen Umgang." [Intercultural Opening in Health Care Promotes Solidarity]. Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)) vol. (2020). doi: https://doi.org/10.1055/a-1236-3630
Beck P, Mratschkowski A, Matusiewicz D. Interkulturelle Öffnung im Gesundheitswesen fördert einen solidarischen Umgang. [Intercultural Opening in Health Care Promotes Solidarity]. Gesundheitswesen. 2020 Oct 23; doi: 10.1055/a-1236-3630. Epub 2020 Oct 23. German. PMID: 33096580.
Copy Download .nbib Format: NLM
Resistin levels in perivascular adipose tissue and mid-term mortality in patients undergoing coronary artery bypass grafting.

Physiological research

Rachwalik M, Obremska M, Zyśko D, Matusiewicz M, Protasiewicz M, Jasiński M.
PMID: 34062078
Physiol Res. 2021 Aug 31;70(4):543-550. doi: 10.33549/physiolres.934661. Epub 2021 Jun 01.

Higher serum resistin levels were reported to be associated with increased mortality risk. We aimed to assess the predictive value of resistin levels in perivascular adipose tissue (PVAT) around the left main coronary artery (LMCA) for mid-term survival of...

Cite
Rachwalik M, Obremska M, Zyśko D, et al. Resistin levels in perivascular adipose tissue and mid-term mortality in patients undergoing coronary artery bypass grafting. Physiol Res. 2021;70(4):543-550doi: 10.33549/physiolres.934661.
Rachwalik, M., Obremska, M., Zyśko, D., Matusiewicz, M., Protasiewicz, M., & Jasiński, M. (2021). Resistin levels in perivascular adipose tissue and mid-term mortality in patients undergoing coronary artery bypass grafting. Physiological research, 70(4), 543-550. https://doi.org/10.33549/physiolres.934661
Rachwalik, M, et al. "Resistin levels in perivascular adipose tissue and mid-term mortality in patients undergoing coronary artery bypass grafting." Physiological research vol. 70,4 (2021): 543-550. doi: https://doi.org/10.33549/physiolres.934661
Rachwalik M, Obremska M, Zyśko D, Matusiewicz M, Protasiewicz M, Jasiński M. Resistin levels in perivascular adipose tissue and mid-term mortality in patients undergoing coronary artery bypass grafting. Physiol Res. 2021 Aug 31;70(4):543-550. doi: 10.33549/physiolres.934661. Epub 2021 Jun 01. PMID: 34062078.
Copy Download .nbib Format: NLM
Showing 25 to 32 of 32 entries